Sab Biotherapeutics Inc (SABS) Stock Price, Quote & News

Company Profile

SAB Biotherapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on the development of human polyclonal immunotherapeutic antibodies to address immune system disorders. It has applied advanced genetic engineering to develop transchromosomic for hyperimmunization and plasma collection, as well as develops product to treat diseases, including type 1 diabetes (T1D) and other autoimmune disorders. In addition, its lead product candidate SAB-142, a human, multi-target anti-thymocyte glo...

Industry: Biotechnology

Sector: Healthcare

Phone: 605 679 6980

Website: www.sabbiotherapeutics.com

Address:

777 W 41st St., Miami Beach, United States

Powell65311 Sep. 15 at 12:36 AM

$AMIX $SABS $BRIA $XTNT $COCH

0 · Reply

BigTimePennyStocks Sep. 14 at 5:22 PM

Small-Caps with Catalysts this week: 👇👇 ( $AMIX, $SABS, $BRIA, $XTNT, $COCH, etc...) #NASDAQ #NYSE

0 · Reply

JTebow_CWS Sep. 12 at 9:10 PM

$SABS $SABSW Today’s LinkedIn post.

0 · Reply

RRGM Sep. 8 at 8:02 PM

$SABS someone bought 96K shares all at once today

1 · Reply

DDiamond_Handz Sep. 2 at 10:05 PM

$SABS like how they waited until 6pm to tell us they are selling 250mill commons...

1 · Reply

JTebow_CWS Aug. 31 at 10:41 PM

$SABS Warrants and options have multi-year motivation.

1 · Reply

DDiamond_Handz Aug. 29 at 2:54 PM

$SABS almost there

0 · Reply

JTebow_CWS Aug. 29 at 1:35 PM

$SABS All optioned up now.

2 · Reply

Goatcheese Aug. 27 at 4:50 PM

$SABS very quite here

1 · Reply

JTebow_CWS Aug. 24 at 7:59 PM

$SABS Another board member William J. Polvino, M.D https://bridgemedicines.com/press-releases/bridge-medicines-appoints-william-j-polvino-m-d-as-chief-executive-officer/

1 · Reply

SAB BIO to Deliver Five Presentations Related to SAB-142 at the 2025 Annual Meeting of the European Association for the Study of Diabetes

Aug 7, 2025, 7:30 AM EDT - 5 weeks ago

SAB BIO Reports Second Quarter Financial Results and Highlights Company Updates

Jul 21, 2025, 7:30 AM EDT - 2 months ago

SAB BIO Announces Oversubscribed $175 Million Private Placement

May 9, 2025, 9:00 AM EDT - 4 months ago

SAB BIO Announces Q1 2025 Financial Results and Provides Company Updates

Mar 31, 2025, 7:32 AM EDT - 6 months ago

SAB BIO Reports Full Year 2024 Operating and Financial Results

Jan 31, 2025, 7:00 AM EST - 8 months ago

SAB BIO to Participate in Upcoming Investor Conferences

Jan 28, 2025, 3:40 PM EST - 8 months ago

Why Is SAB BIO Stock Trading Lower On Tuesday?

Jan 28, 2025, 7:00 AM EST - 8 months ago

SAB BIO Announces Positive Topline Phase 1 Clinical Results with Potentially Disease-Modifying T1D Therapy SAB-142

Jan 23, 2025, 7:00 AM EST - 8 months ago

SAB BIO Announces R&D Webinar Event to Review Phase 1 Topline Results for SAB-142, a Disease-Modifying T1D Therapy

Nov 6, 2024, 5:05 PM EST - 11 months ago

SAB BIO Announces Third Quarter 2024 Financial Results and Provides Company Update

Sep 13, 2024, 7:00 AM EDT - 1 year ago

SAB BIO CEO to Participate in Fireside Chat at 2024 Cantor Global Healthcare Conference

Sep 4, 2024, 7:05 AM EDT - 1 year ago

SAB BIO to Present at the European Association for the Study of Diabetes 60th Annual Meeting

Aug 8, 2024, 5:51 PM EDT - 1 year ago

SAB BIO Announces Second Quarter 2024 Financial Results and Provides Company Updates

Aug 5, 2024, 7:30 AM EDT - 1 year ago

SAB BIO Announces Founding of Clinical Advisory Board to Guide the Development of SAB-142 for Type 1 Diabetes

Jul 31, 2024, 7:30 AM EDT - 1 year ago

SAB BIO Appoints Lucy To as Chief Financial Officer

Jun 20, 2024, 7:20 AM EDT - 1 year ago

SAb Biotherapeutics Rebrands as SAB BIO

Jun 18, 2024, 1:10 PM EDT - 1 year ago

SAB Biotherapeutics to Present at the American Diabetes Association 84th Scientific Sessions

May 30, 2024, 4:45 PM EDT - 1 year ago

SAB Biotherapeutics Announces Departure of Chief Financial Officer

May 21, 2024, 7:15 AM EDT - 1 year ago

FDA Provides Clearance to IND Application for Type 1 Diabetes Therapy SAB-142 by SAB Biotherapeutics

May 20, 2024, 5:45 PM EDT - 1 year ago

SAB Biotherapeutics Announces Q1 2024 Financial Results and Provides Company Updates

May 6, 2024, 7:15 AM EDT - 1 year ago

SAB Biotherapeutics Appoints Jay Skyler, MD, to the Board of Directors

Apr 16, 2024, 7:15 AM EDT - 1 year ago

SAB Biotherapeutics Provides SAB-142 Trial Update

Apr 8, 2024, 7:15 AM EDT - 1 year ago

SAB Biotherapeutics to Present at INNODIA Annual Meeting

Apr 4, 2024, 7:15 AM EDT - 1 year ago

SAB Biotherapeutics to Present at the Needham Virtual Healthcare Conference

Mar 29, 2024, 7:15 AM EDT - 1 year ago

SAB Biotherapeutics Reports Full Year 2023 Operating and Financial Results

Mar 25, 2024, 10:15 AM EDT - 1 year ago

SAB Biotherapeutics Announces Clinical Partnership with Naval Medical Research Center to Advance Potential Influenza Treatment

Feb 23, 2024, 8:00 AM EST - 1 year ago

SAB Biotherapeutics to Present at the BIO CEO & Investor Conference

Feb 8, 2024, 8:00 AM EST - 1 year ago

SAB Biotherapeutics to Present at the Oppenheimer 34th Annual Healthcare Life Sciences Conference

Feb 2, 2024, 7:30 AM EST - 1 year ago

SAB Biotherapeutics Announces Executive Leadership Change

Jan 23, 2024, 5:58 PM EST - 1 year ago

SAB Biotherapeutics Regains Compliance with Nasdaq Minimum Bid Price Requirement

Jan 2, 2024, 4:30 PM EST - 1 year ago

SAB Biotherapeutics Announces 1-for-10 Reverse Stock Split

Nov 29, 2023, 7:30 AM EST - 1 year ago

SAB Biotherapeutics Announces Commencement of the HUMAN Phase 1 Clinical Trial with SAB-142, a Potential Disease-Modifying Treatment for Type 1 Diabetes

Nov 20, 2023, 7:30 AM EST - 1 year ago

SAB Biotherapeutics Appoints Katie Ellias to the Board of Directors

Nov 14, 2023, 7:30 AM EST - 2 years ago

SAB Biotherapeutics Announces Completion of $67.1 Million Financing to Advance Potential Disease-Modifying Treatment for Type 1 Diabetes

Nov 14, 2023, 7:15 AM EST - 2 years ago

SAB Biotherapeutics Announces Q3 2023 Financial Results and Provides Company Updates

Nov 9, 2023, 7:30 AM EST - 2 years ago

SAB Biotherapeutics to Present at Piper Sandler Healthcare Conference

Oct 24, 2023, 7:30 AM EDT - 2 years ago

SAB Biotherapeutics Appoints Michael G. King Jr. as Chief Financial Officer

Oct 19, 2023, 7:30 AM EDT - 2 years ago

SAB Biotherapeutics Receives Australian Approval to Commence Phase 1 Clinical Trial of SAB-142, a Potential Disease-Modifying Treatment for Type 1 Diabetes

Oct 5, 2023, 7:30 AM EDT - 2 years ago

SAB Biotherapeutics Approves Appointment of Andrew Moin to Board of Directors

Oct 2, 2023, 7:30 AM EDT - 2 years ago

SAB Biotherapeutics Announces Private Placement of up to $130 Million to Advance Development of Lead Drug Candidate for Type 1 Diabetes

Powell65311 Sep. 15 at 12:36 AM

$AMIX $SABS $BRIA $XTNT $COCH

0 · Reply

BigTimePennyStocks Sep. 14 at 5:22 PM

Small-Caps with Catalysts this week: 👇👇 ( $AMIX, $SABS, $BRIA, $XTNT, $COCH, etc...) #NASDAQ #NYSE

0 · Reply

JTebow_CWS Sep. 12 at 9:10 PM

$SABS $SABSW Today’s LinkedIn post.

0 · Reply

RRGM Sep. 8 at 8:02 PM

$SABS someone bought 96K shares all at once today

1 · Reply

DDiamond_Handz Sep. 2 at 10:05 PM

$SABS like how they waited until 6pm to tell us they are selling 250mill commons...

1 · Reply

JTebow_CWS Aug. 31 at 10:41 PM

$SABS Warrants and options have multi-year motivation.

1 · Reply

DDiamond_Handz Aug. 29 at 2:54 PM

$SABS almost there

0 · Reply

JTebow_CWS Aug. 29 at 1:35 PM

$SABS All optioned up now.

2 · Reply

Goatcheese Aug. 27 at 4:50 PM

$SABS very quite here

1 · Reply

JTebow_CWS Aug. 24 at 7:59 PM

$SABS Another board member William J. Polvino, M.D https://bridgemedicines.com/press-releases/bridge-medicines-appoints-william-j-polvino-m-d-as-chief-executive-officer/

1 · Reply

JTebow_CWS Aug. 24 at 7:53 PM

$SABS Another Director Go Hurricanes. https://www.um-jmhendocrinology.com/jay-s-skyler-md

1 · Reply

JTebow_CWS Aug. 23 at 2:10 AM

$SABS $SABSW Thoughts?

1 · Reply

DDiamond_Handz Aug. 22 at 7:13 PM

$SABS

0 · Reply

JTebow_CWS Aug. 21 at 2:28 AM

$SABS John Wentworth MBBS, FRACP, Professor of Medicine in Australia. Another Clinical Board member on SAB BIO. He’s seems to be talking about TZIELD that delays Type 1 by 2 years. I’m thankful we may finally be on a path to permanently delay this horrible child onset disease. https://youtu.be/K_L_Td3KW3g?si=GhhfsWmjfJT4zjQW

0 · Reply

JTebow_CWS Aug. 20 at 6:34 PM

$SABS Miami has been known recognized leader in research for a long time. Jay S. Skyler, MD, MACP is currently a Professor of Medicine, Pediatrics, & Psychology, in the Division of Endocrinology Diabetes & Metabolism, Department of Medicine, University of Miami Leonard M. Miller School of Medicine, Miami, Florida https://diabetesresearch.org/jay-skyler/

0 · Reply

JTebow_CWS Aug. 20 at 6:30 PM

$SABS Belgium lead endocrinologist on SAB BIO clinical board. https://www.diabetestechnology.org/dtm/bios/2022/mathieu.html

2 · Reply

DDiamond_Handz Aug. 20 at 6:21 PM

$SABS

0 · Reply

JTebow_CWS Aug. 20 at 1:13 PM

$SABS USA, Great Britain, and Australia researchers on this project. https://www.svi.edu.au/researchers/professor-tom-kay/

1 · Reply

JTebow_CWS Aug. 20 at 1:10 PM

$SABS Another founding clinical board member. https://diabetes.ucsf.edu/people/stephen-gitelman

0 · Reply

JTebow_CWS Aug. 20 at 11:14 AM

$SABS https://ufhealth.org/doctors/michael-j-haller/bio

0 · Reply

JTebow_CWS Aug. 20 at 11:12 AM

$SABS One of the Board Members on SAB BIO. https://profiles.cardiff.ac.uk/staff/dayancm

0 · Reply

JTebow_CWS Aug. 20 at 12:58 AM

$SABS Not going bankrupt anytime soon. Peter Lynch said, it’s hard to go bankrupt when you don’t have any debt.

0 · Reply

Market Cap	21.86M
Revenue (ttm)	1.32M
Net Income (ttm)	-34.11M
EPS (ttm)	N/A
PE Ratio	0.00
Forward PE	N/A
Profit Margin	-2,584.09%
Debt to Equity Ratio	0.00

Volume	70,000
Avg Vol	1,787,396
Day's Range	N/A - N/A
Shares Out	10.41M
Stochastic %K	39%
Beta	0.54
Analysts	Strong Sell
Price Target	$9.60